Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nabiximols + temozolomide
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oromucosal, Oral
01
Overview
Nabiximols + temozolomide is a combination therapy under investigation for the treatment of recurrent glioblastoma multiforme (GBM). Nabiximols (marketed as Sativex) is an oromucosal spray containing a standardized extract of Cannabis sativa with a 1:1 ratio of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), acting primarily on cannabinoid receptors in the central nervous system. Temozolomide is an oral alkylating agent used as chemotherapy, which induces DNA damage in tumor cells leading to cell death. The combination aims to leverage potential synergistic antitumor effects, with nabiximols possibly enhancing the cytotoxicity of temozolomide against GBM cells. Clinical trials have shown that this combination has acceptable safety and tolerability profiles, with preliminary evidence suggesting improved survival compared to standard therapy alone[1][2][3][4][5][8].
- Brand names
- Sativex + Temodar
- Other names
- nabiximols + temozolomideSativex + temozolomide
02
Targets
CNR1 (Cannabinoid receptor 1)DNA
Beyond the preview
Go deeper on nabiximols + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nabiximols + temozolomide.